Onyx Pharmaceuticals: Focus Is a Double-edged Sword
• By Mark Ratner
Onyx Pharmaceuticals announced last June that it would focus solely on its lead product candidate, BAY 43-9006, in Phase III and partnered with Bayer. Its stock has since soared. The company is responsible for some development, and so maintains an active clinical capability. It also negotiated a US co-promotion right. Both may make it an attractive in-licensor, but more than infrastructure, its greatest validation and attraction will come from showing that management made the right choice in prioritizing. It's an all-or-nothing bet, to be sure.
It's a truism in biotech that when it comes to raising money,
the time to eat is when the food is on the table. But investors
don't put money into biotech companies only to see it sit in the
bank.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
Cancer assets drove the highest percentage of biopharma alliance dealmaking in 2024, tripling the frequency of the next highest therapeutic category, neurology.
Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.
Deal Snapshot: Sanofi obtained global rights to a pair of bispecific antibody candidates for autoimmune and inflammatory bowel disorders from Helixon-affiliated AI firm Earendil.
Restructuring Edition: ESSA and Elevation are reviewing strategic alternatives after trial failures, but each has an investor urging them to liquidate. Also, Third Harmonic and Vincerx are winding down, while Keros and Tempest are assessing options, but Opthea and OPM are cutting jobs.
